12th November, 2026

To,

National Stock Exchange of India,
Listing Department,
Bandra Kurla Complex
Bandra East,
Mumbai - 400 051

SYMBOL: KILITCH

BSE Limited,
Department of Corporate Services - Listing,
Phiroze Jeejebhoy Towers,
Dalal Street,
Mumbai- 400 001

Scrip Code: 524500

Dear Sir / Madam,

Sub: Intimation under Regulation 30(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable SEBI regulations.

In continuation of the outcome of the meeting of the Board of Directors ("**Board**") of Kilitch Drugs (India) Limited ("**Company**") submitted to the Stock Exchanges on October 22, 2026, pursuant to which the Board had, inter alia, approved the proposed conversion of the entire outstanding debt including service cost aggregating up to INR 57.00 crore extended by the Company to Kilitch Estro Biotech PLC ("**KEB**" or the "**Material Subsidiary**") into equity shares of KEB ("**Conversion**"), and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**Listing Regulations**"), we intimate you of the following update:

- Due to a typographical error, the number of equity shares of KEB to be allotted to the Company upon completion of the Conversion was inadvertently mentioned as 1,66,472 (One Lakh Sixty-Six Thousand Four Hundred and Seventy-Two) equity shares instead of 1,66,471 (One Lakh Sixty-Six Thousand Four Hundred and Seventy-One) equity shares. Further, the price at which such shares were to be acquired was inadvertently mentioned as INR 3,414 (Rupees Three Thousand Four Hundred and Fourteen only) per share instead of INR 3,413.23 (Rupees Three Thousand Four Hundred and Thirteen and Twenty-Three Paise only) per share.

Accordingly, Point No. 8, titled "Cost of Acquisition and/ local norms the price at which the shares are acquired", and Point No. 9, titled "Percentage of shareholding / control acquired and / or number of shares acquired", of Annexure B to the outcome of the Board Meeting dated October 22, 2026, shall stand modified to reflect the rectified acquisition price of INR 3,413.23 (Rupees Three Thousand Four Hundred and Thirteen and Twenty-Three Paise only) per equity share and the rectified number of 1,66,471 (One Lakh Sixty-Six Thousand Four Hundred and Seventy-One) equity shares, respectively.

Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. • Tel.: +91-22-6121 4100 • Fax : +91-22-6703 1658
Registered Office & Manufacturing unit : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra.
• CIN: L24239MH1992PLC066718 • Tel.: +91-22-6299 6300 • Fax : +91-22-2768 0912 • E-mail : info@kilitch.com • Website : www.kilitch.com

Except for the rectification expressly set out herein and the consequential change arising therefrom, all other terms and conditions of the proposed Conversion, as approved earlier by the Board, shall remain unchanged.

We kindly request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND PRATAPRAI MEHTA

Digitally signed by MUKUND PRATAPRAI MEHTA
Date: 2026.11.12 18:39:29 +05'30'

Mukund Mehta
Managing Director